Compounds > phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide
Page last updated: 2024-09-03

phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide and Epithelial Ovarian Cancer

phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide has been researched along with Epithelial Ovarian Cancer in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Cheng, JC; Fang, L; Jia, Q; Leung, PCK; Liu, B; Wu, Z1

Other Studies

1 other study(ies) available for phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide and Epithelial Ovarian Cancer

ArticleYear
NPFF stimulates human ovarian cancer cell invasion by upregulating MMP-9 via ERK1/2 signaling.
    Experimental cell research, 2023, 09-01, Volume: 430, Issue:1

    Topics: Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Humans; MAP Kinase Signaling System; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Ovarian Neoplasms; Signal Transduction

2023